IFNA1 and colorectal carcinoma: These results are consistent with previous preclinical work indicating that the intrahepatic delivery of IFNα through a gene/cell therapy approach curbs CRC liver metastases by acting primarily on unidentified non-hematopoietic stromal cell populations (Catarinella et al., 2016).